Drug news
CHMP recommends Picato (Leo Pharma) for treatment of Actinic Keratosis
On 20 September 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Picato, 150 micrograms/g, 500 micrograms/g gel intended for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic Actinic Keratosis in adults. The applicant for this medicinal product is LEO Pharma A/S.